Status: Not yet recruiting
Study on Doses of Inhaled ALX1 in Adults With Bronchiectasis
This study will evaluate the safety and effects of ALX1, an inhaled investigational treatment, in adults with bronchiectasis. Participants will receive either ALX1 or a placebo (a treatment with no active medicine) for 14 days. The study will compare different dose levels of ALX1 to help identify appropriate doses for future research based on safety, tolerability, and changes in predictive biomarkers.
Participants needed: 28
Trial details
Phase: Phase 2Age: 18-80Biological sex: AllType: InterventionalSponsor: Vast TherapeuticsUpdated: Jul 28, 2026
Eligibility criteria
Current sputum producer with a history of chronic expectoration that, in the opi... [+6]
Negative sputum NEATstik result for neutrophil elastase at Pre-screening. [+15]